337 results on '"Hiatt, William R"'
Search Results
2. Peripheral Arterial Disease Handbook
3. Lessons Learned from a Phase I Clinical Trial of Mitochondrial Complex I Inhibition
4. Antiplatelet Therapy in Peripheral Artery Disease
5. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
6. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials
7. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial
8. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
9. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization
10. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial
11. World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial
12. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial
13. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization
14. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial
15. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial
16. Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID
17. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial
18. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease
19. Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization
20. Reply to “The VOYAGER PAD Trial in Surgical Perspective: A Debate”
21. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
22. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial
23. Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial
24. Pathophysiology of Peripheral Artery Disease, Intermittent Claudication, and Critical Limb Ischemia
25. Contributors
26. Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease
27. Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia
28. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
29. Plantar Flexion–Induced Entrapment of the Dorsalis Pedis Artery in a Teenaged Cross-Country Runner
30. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization
31. Antiplatelet Therapy in Peripheral Artery Disease
32. Medical Treatment of Peripheral Arterial Disease
33. Abstract 14141: A Contemporary Assessment of Lipid Lowering Therapies and Low-density Lipoprotein Cholesterol in Peripheral Artery Disease
34. Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD
35. Abstract 13462: 6-minute Walk Test Variability May be Reduced by a Structured Training and Monitoring Program, Potentially Facilitating Detection of Treatment Effects
36. Abstract 16512: Amputation in Patients With Pad With and Without Diabetes: Insights From the EUCLID Trial
37. Abstract 17116: Incidence and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization
38. Abstract 15943: Health Status and Quality of Life With Early Invasive and Non-invasive Treatment Strategies for Patients With Claudication
39. Abstract 16190: Trends in Admissions and Outcomes in Patients With Chronic Limb-threatening Ischemia-a National Inpatient Sample Analysis
40. Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
41. Automated Detection of Exercise Sessions in Patients With Peripheral Artery Disease
42. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
43. Cause of Death Among Patients With Peripheral Artery Disease
44. Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial
45. Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease
46. Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease
47. Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease
48. Association of Perceived Stress Levels With Long-term Mortality in Patients With Peripheral Artery Disease
49. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
50. Rivaroxaban in Peripheral Artery Disease after Revascularization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.